Recent

% | $
Quotes you view appear here for quick access.

Corrections Corporation of America Message Board

mecosmo2 49 posts  |  Last Activity: 16 hours ago Member since: May 19, 1999
  • BAC should be $25 by 2017 or MORE!

    Sentiment: Strong Buy

  • BAC had two upgrades in late Jan. 2016 here's one
    Jan 20, 2016 Sandler O'Neill Upgrade to Buy
    If the earning estimates are correct $1.68 BAC should be $25 by 2017

    .

    Jan 20, 2016 Sandler O'Neill Upgrade to Buy
    If the earning estimates are correct $1.68 BAC should be $25 by 2017

    Sentiment: Strong Buy

  • Jan 20, 2016 Sandler O'Neill Upgrade to Buy
    If the earning estimates are correct $1.68 BAC should be $25 by 2017

    Sentiment: Strong Buy

  • BAC earnings estimate of $1.68 and a PE of 15 it shoulds be at $25. PPS

    Sentiment: Strong Buy

  • The BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies. Because our mission is to support industry-wide success, we present a broad and unbiased view of investment opportunities.
    The conference features issue-oriented plenary sessions, educational sessions focused on hot therapeutic areas and key business issues, company presentations, one-on-one meetings, and networking opportunities.
    Our therapeutic workshops feature MDs, CSOs and industry analysts discussing the latest information on pipeline innovation for breakthrough therapeutic topics in biopharma. Seasoned industry executives and analysts delve into timely and relevant business models, deal-making and investment trends on our business roundtables.

    Sentiment: Strong Buy

  • Median target price: $19 (43% upside)
    Positive ratings: 90% of 10 analysts
    Latest: Credit Agricole | outperform | 01/29

    Sentiment: Strong Buy

  • Bank of America shares were already down a sharp 17% so far in 2016 ahead of Tuesday. A recent analyst upgrade was too big to ignore. Mike Mayo, the esteemed banking analyst at CLSA, raised his rating to Outperform from Sell and raised his target to $16.00 from $15.00. That may be under the consensus target of $18 by some amount, but Mayo had been consistently bearish on Bank of America.

    Sentiment: Strong Buy

  • -- CLSA Americas Managing Director Mike Mayo discusses his outlook for the banking industry. Franklin Square CEO Michael Forman also speaks on "Bloomberg ‹GO›." Mayo owns no stock in BofA. said its a BUY now!

    Sentiment: Strong Buy

  • Bank of America Merrill Lynch Community Development Banking (CDB) provided a record-setting $4.5 billion in equity and lending, the most in a single year in its more than 30-year history.

    In 2015, the Community Development Banking group also completed its single largest transaction – the San Francisco Rental Assistance Demonstration (SF-RAD). The bank provided $770 million as investor and lender on the deal, which will transform more than 1,400 public housing units at 15 properties into safe and sustainable low-income housing for San Francisco residents. CDB provided an innovative combination of construction debt, permanent debt, tax-credit equity, subordinate forgivable debt, and financing for services for tenants as part of its continued commitment to create strong communities. No existing tenants will be displaced, and affordability will be maintained at existing levels. In addition to safety and aesthetic improvements, other changes will include seismic upgrades and systems, roof, exterior and energy efficiency updates.

    Sentiment: Strong Buy

  • 2016 02-01-16 dividend payout of .48 per share

    Sentiment: Strong Buy

  • During the worst start to a year, ever, while many stocks have entered a bear market and lost 20% or more of their value, T has varied barely 4% from top to bottom.
    It ranged from $35 at the start of the correction, touched $33.50 and bounced back to $35.53, finishing higher than when the correction began. This stock left thousands of other companies in the dust and raised the dividend a penny a quarter to boot.
    This is the kind of performance that can bolster an investor's confidence while everything else is falling apart around him. Too often, we see investors panic when volatility rears its ugly head. With this lack of volatility and stable performance an investor will have no reason to cut and run.

    Sentiment: Strong Buy

  • Heading for take out of old 36. 50 high and investors are looking for dividend and safety!!

    Sentiment: Strong Buy

  • The investors are waiting for. .Top-Line Phase 2b Data for Fispemifene Expected in Q1 2016 Hang in there Boyz it will happen in about 60 days!!2016

    Sentiment: Strong Buy

  • Fispemifene is a once daily orally administered selective estrogen receptor modulator (SERM) in development for multiple urological conditions in men. A Phase 2 clinical trial is expected to commence during the first half of 2015 to confirm the optimal fispemifene doses to treat men with secondary hypogonadism, and provide proof-of-concept data to evaluate the the relief of symptoms associated with this condition.
    Fispemifene acts in secondary hypogonadism by inhibiting the negative feedback of testosterone production via an estrogen-blocking effect at the level of the pituitary, resulting in increased testosterone production in the testes, which in turn restores circulating testosterone levels to within, but not beyond, the normal range. In line with fispemifene’s mechanism of action, the treatment has been shown in Phase 2a studies involving a total of 149 hypogonadal men to normalize testosterone levels while retaining and, in some men, restoring testicular function, a feature of importance for infertile younger men with hypogonadal symptoms.
    Additionally, in line with fispemifene’s anti-estrogenic action on the lower urinary tract (LUT), no negative effects on prostate volume, prostate specific antigen (PSA), or urodynamic obstructive symptoms were observed. Expanding on these observations seen in three-month clinical studies in hypogonadal men, preclinical studies involving fispemifene have shown the potential beneficial anti-estrogenic effects of fispemifene of reducing prostate volume and inflammation and improving urodynamics, opening up additional potential indications for this SERM in men with obstructive LUT conditions and chronic prostatitis.

    Sentiment: Strong Buy

  • Denner;s big buy will spark a run up for apri Momentum is building via twitter!! All aboard!!

    Sentiment: Strong Buy

  • UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    January 12, 2016
    ORDER GRANTING CONFIDENTIAL TREATMENT
    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Apricus Biosciences, Inc.
    File No. 0-22245 -CF#33163
    _____________________
    Apricus Biosciences, Inc. submitted an application under Rule 24b-2 requesting
    confidential treatment for information it excluded from the Exhibits to a Form 10-Q filed
    on November 5, 2015.
    Based on representations by Apricus Biosciences, Inc. that this information
    qualifies as confidential commercial or financial information under the Freedom of
    Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined
    not to publicly disclose it. Accordingly, excluded information from the following
    exhibit(s) will not be released to the public for the time period(s) specified:
    Exhibit 10.1 through November 5, 2025
    For the Commission, by the Division of Corporation Finance, pursuant to
    delegated authority:
    Brent J.

    Sentiment: Strong Buy

  • 2015 Accomplishments:
    Initiated and completed enrollment in its fispemifene Phase 2b clinical trial for the treatment of symptomatic male secondary hypogonadism;
    According to IMS Midas, over 633,000 Vitaros units sold in Europe in 2015 through November;
    Vitaros® monthly sales in Europe tracked on a 111,000 monthly unit run rate, which is expected to grow in both existing markets and new markets with additional launches throughout 2016 by our commercialization partners;
    Completed and reported top-line data on the Phase 2a clinical trial of RayVa™ for Raynaud's phenomenon secondary to scleroderma;
    Licensed the U.S. development and commercialization rights for Vitaros from Allergan plc; and
    Expanded Vitaros partnerships to include parts of Asia, Eastern Europe and Latin America.
    Goals and Priorities for 2016
    Apricus will continue to leverage Vitaros as a cash-generating asset through royalty and milestone payments and by expanding the product's market reach via additional ex-U.S. launches by our commercialization partners;
    Apricus expects to obtain European approval for one or more variations to the approved Vitaros product with the goal of enhancing the profile of Vitaros; Re: RTD
    Apricus expects to re-submit the New Drug Application (NDA) for Vitaros’ approval in the U.S. in the second half of 2016;
    Apricus plans to complete the Phase 2b clinical trial and report top-line data for fispemifene in symptomatic secondary hypogonadism in the first quarter 2016. Positive results from this trial, if achieved, would position Apricus to move fispemifene into additional late-stage clinical trials, when appropriate. Apricus will also continue development of fispemifene in Lower Urinary Tract Symptoms (LUTS) throughout 2016;
    [color=red]Apricus expects to initiate a Phase 2b at-home dosing clinical trial with RayVa in the second half of 2016.

    Sentiment: Strong Buy

  • Daily application of alprostadil topical cream (Vitaros) does not impact vaginal pH, flora, or histology in female cynomolgus monkeys.
    Meier-Davis SR1, Debar S2, Siddoway J3, Rabe M3.
    Author information
    Abstract
    Topical alprostadil cream (Vitaros) is approved in Canada and Europe for the treatment of erectile dysfunction. To determine the effects on the female urogenital tract with repeated administration of the entire dose (300 μg alprostadil containing 2.5% dodecyl-2-n,n-dimethylaminopropionate hydrochloride), the vaginal pH, flora, and histology were assessed as a model for 100% transference from male to the female during unprotected sexual intercourse. Female cynomolgus monkeys were administered the entire dose of Vitaros for 14 days with a 7-day recovery. Relative to vehicle and placebo cream, the vaginal pH and microflora were determined at baseline and weekly, thereafter. Vaginal biopsies were evaluated at the end of dosing and recovery. All animals were clinically normal for the study duration, and the vaginal pH was consistent between dose groups and the dosing period. Vaginal microflora and histopathology findings of mild inflammation were generally similar across treatment groups. In conclusion, repeated vaginal exposure to Vitaros did not alter the pH, microflora, or histology after 14 daily doses, supporting the safety of Vitaros transference to the female partner.

    Sentiment: Strong Buy

  • mecosmo2 mecosmo2 Jan 5, 2016 11:41 AM Flag

    FDA SCHEDULE apri phase 2B on 3/31.2016 for Fispemifene

    Sentiment: Strong Buy

  • FDA schedule apri phase 2B on 3/31.2016 for FIS!!

    Sentiment: Strong Buy

CXW
29.27-0.57(-1.91%)Feb 5 4:04 PMEST